Interim Report – January to June 2021

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®, today issued its Second Quarter Report for 2021.

Financial Highlights April – June, 2021

• Revenue SEK 9.6 (109.6) m
• Operating result SEK -92.4 (9.5) m
• Net result SEK -93.5 (8.1) m
• Cash and cash equivalents SEK 61.4 (277.5) m
• Cash flow for the period SEK 20.1 (-18.9) m

Significant Events during the period April – June, 2021

• On May 3, 2021 Affibody Medical AB (publ) received a SEK 100.0 m loan from its major shareholder Duba AB, a subsidiary within the Investor group.
• On June 30, 2021 the loan was converted into a convertible debenture at the AGM. All other shareholders have been offered the opportunity to subscribe for convertible debentures on the same terms as Duba AB.

Significant Events after the reporting period

• First patient’s first dose in the axSpA Phase II study with ABY-035 conducted together with partner Inmagene.
• Convertible debentures for an amount of SEK 106.1 m were subscribed for.